Relief Therapeutics Holding's quarterly market cap
increased
from Jun. 2024 (CHF15.05 Mil) to Dec. 2024 (CHF52.79 Mil) but then
declined
from Dec. 2024 (CHF52.79 Mil) to Jun. 2025 (CHF26.91 Mil).
Relief Therapeutics Holding's annual market cap
declined
from Dec. 2022 (CHF132.17 Mil) to Dec. 2023 (CHF24.95 Mil) but then
increased
from Dec. 2023 (CHF24.95 Mil) to Dec. 2024 (CHF52.79 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Relief Therapeutics Holding's Enterprise Value for Today is CHF27.18 Mil.
Relief Therapeutics Holding (XSWX:RLF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Relief Therapeutics Holding Market Cap Related Terms
Relief Therapeutics Holding Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:RLF vs KTTA, OSRH, LIMN: Market Cap Comparison
For the Biotechnology subindustry, Relief Therapeutics Holding's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relief Therapeutics Holding Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Market Cap distribution charts can be found below:
* The bar in red indicates where Relief Therapeutics Holding's Market Cap falls into.
Relief Therapeutics Holding Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relief Therapeutics Holding (XSWX:RLF) has a Market Cap of CHF37.78 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Relief Therapeutics Holding and its competitors.
Is Relief Therapeutics Holding's Market Cap too high?
Relief Therapeutics Holding's current Market Cap is CHF37.78 Mil. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's Market Cap compare to KTTA and OSRH?
Relief Therapeutics Holding's Market Cap of CHF37.78 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 113.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Relief Therapeutics Holding and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relief Therapeutics Holding's current Market Cap is CHF37.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current Market Cap of CHF37.78 Mil. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current Market Cap is CHF37.78 Mil. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current Market Cap is CHF37.78 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?
Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued.
The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.
Key valuation signals for XSWX:RLF:
Market Cap: CHF37.78 Mil
GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score
Get the complete analysis for XSWX:RLF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RLF has been successfully added to your 
